Researchers at Memorial Sloan Kettering Cancer Center have discovered that Bacillus Calmette-Guérin (BCG) therapy reprograms and amplifies cells in the bone marrow, enhancing the innate immune system's ability to combat cancer. This breakthrough could lead to improved immunotherapies for various cancers.
Researchers at MSK uncovered a key signaling molecule involved in the body's immune response against leptomeningeal metastasis. A new grading system to assess thrombocytopenia risk after CAR T cell therapy was also developed. Additionally, a statistical method called UnitedMet estimates metabolic characteristics from challenging clinic...
Thetis cells, a newly discovered class of immune cells, play a crucial role in suppressing inflammatory responses to food and promoting oral tolerance. The discovery opens the door to new therapeutic possibilities for treating food allergies.
A new study found that pregnancy-related glycoproteins (PSGs) are strongly associated with poorer outcomes in female lung cancer patients. The analysis suggests targeting these genes may improve survival in female patients with lung cancer, and the researchers plan to pursue further investigation into their role.
Researchers at Memorial Sloan Kettering Cancer Center have made significant breakthroughs in understanding Acute Myeloid Leukemia (AML) and early brain development. They identified a rare quiescent population of stem cells responsible for disease persistence and therapy resistance, as well as shedding light on gene expression patterns ...
A phase 1 clinical trial found that nerve cells derived from embryonic stem cells can produce dopamine, a chemical lacking in Parkinson's patients. The treatment has been licensed to BlueRock Therapeutics and is expected to proceed to a larger patient group in the first half of 2025.
A new method has been developed for engineering specific mtDNA deletions in human cells, providing a powerful tool to model disease-associated mtDNA deletions. This approach uncovers mechanisms of histiocytosis-associated neurodegeneration and investigates how mutant stem cells co-opt regeneration to make tumors grow.
A team of scientists used cryo-electron microscopy to investigate G-quadruplexes, which have gained attention as potential therapeutic targets in cancer. The study reveals how secondary DNA structures like G4s can impede DNA replication and provides new insights into fundamental human biology.
Researchers at Memorial Sloan Kettering Cancer Center and Weill Cornell Medicine have discovered a vulnerability in the hepatitis B virus that could lead to new treatments. The study found a compound already in clinical trials against cancer that successfully disrupted the virus's ability to infect human liver cells.
The FDA has approved vimseltinib, a targeted therapy, for treating symptomatic tenosynovial giant cell tumor (TGCT). Vimseltinib demonstrated significant reduction in tumor volume and improvement in quality of life for patients, with fewer side effects compared to pexidartinib.
A new treatment, datopotamab deruxtecan, has been approved by the FDA for people with metastatic ER-positive breast cancer. Researchers at Memorial Sloan Kettering Cancer Center have also discovered a new strategy to overcome resistance in prostate cancers, suggesting that targeting mTOR may restore sensitivity. Additionally, an MSK re...
A new liposarcoma treatment using CAR T cells has shown promising results in clinical trials, with a response rate of 20-40% in patients with advanced or metastatic disease. Additionally, researchers have developed more efficient drug-delivery nanoparticles that can improve cancer treatment outcomes.
Researchers at Memorial Sloan Kettering Cancer Center have made a breakthrough in creating allogeneic CAR T cells that can persist in fighting cancer without being rejected by patients. By modifying donor cells with the HIV protein Nef, the cells can survive and remain potent in treating various types of cancer.
MSK researchers contribute to the Human Virome Program, which aims to map viruses living in and on humans. The project seeks to understand how these viruses contribute to human health and disease, potentially revealing links between viral infections and cancer outcomes.
A recent study from Memorial Sloan Kettering Cancer Center sheds new light on the heterogeneity of GBM tumors and the role of cancer stem cells in tumor growth. The research identifies six distinct transcriptional states, each with its own unique gene signature, and provides guidance for future research to develop targeted therapies.
A research team at Memorial Sloan Kettering Cancer Center has identified a novel molecular pathway leading to the formation of tertiary lymphoid structures (TLSs) in tumors. TLSs are immune cell clusters that can boost the local immune response and may be harnessed for immunotherapy treatments.
A new AI-based model, SCORPIO, developed by Memorial Sloan Kettering Cancer Center and Mount Sinai, uses routine blood tests to predict immunotherapy response for various cancer types. The model outperforms current biomarkers in predicting outcomes, offering a more accessible and affordable solution for patient selection.
Researchers at Memorial Sloan Kettering Cancer Center discovered an unrecognized role for ALAS1 in regulating microRNAs, which could improve the efficacy of siRNA drugs against disease-causing genes. The finding offers new potential for developing targeted therapies against cancer and other diseases.
New MSK research sheds light on RAD51 control, gene amplification method and tumor suppressor genes in cancer. A new study develops a method to study gene amplifications in cancer by engineering them in cells and mice using extrachromosomal DNAs.
Researchers at MSK Cancer Center made significant advancements in understanding cancer biology, developing CAR T cells for blood cancers, and creating an AI tool to predict immune checkpoint inhibitor responses. Fasting was also explored as a strategy to reprogram natural killer immune cells and improve cancer-fighting abilities.
Researchers at Memorial Sloan Kettering Cancer Center found that a high fiber plant-based dietary intervention can significantly improve disease progression trajectory in participants with precancerous blood disorder. After 12 weeks, two participants showed a significant improvement and none progressed to multiple myeloma within one year.
Researchers found that as cells age, they lose regenerative capacity and become less susceptible to cancer. The study's findings suggest that therapies targeting ferroptosis may be less effective in older patients.
MSK researchers have identified a compound that selectively kills glioblastoma cells while sparing healthy cells. They also developed a new method to study cancer evolution by introducing mutations in specific genes, allowing for the rapid regression of leukemia and understanding its behavior.
Researchers at Memorial Sloan Kettering Cancer Center have identified a potential therapeutic approach to treat RAS-driven cancers using artificial intelligence. Additionally, they developed a new model for investigating lung cancer metastasis and uncovered how changes to helper proteins drive cancer cell survival.
Recent studies by MSK researchers show that the innate immune system helps maintain genome stability during DNA replication, and chronic activation can contribute to tumor development. The findings also suggest that problems with a protein complex called Mre11 can create an environment where cancer is more likely to occur.
Researchers have discovered a therapeutic approach that shows promise in preclinical models for treating cancers driven by RAS mutations. The study found that tri-complex inhibitors can restore the normal functioning of mutated RAS proteins, aiming to correct the defect that drives cancer growth.
A new MSK study has identified patterns in how cancer cells reprogram themselves during metastasis, providing new details on cellular plasticity. The research team compared samples from patients with advanced colorectal cancer and found clear patterns in the way metastatic cells change their identity to access early cell states.
Researchers have discovered that ASCL1 is essential to the transformation of adenocarcinoma into neuroendocrine prostate cancer, a deadly form of the disease. Disabling the ASCL1 gene can prevent this transition, but only if done early in the disease progression.
Researchers have found that tumors with a short-lived response to hormone therapy had a mutation in the p53 gene, which can be targeted by CDK2 inhibitors. A new study also provides updated dosing guidelines for stereotactic body radiation therapy (SBRT) to minimize complications in patients with spinal metastasis.
A new subtype of small cell lung cancer has been identified that primarily affects younger people who have never smoked. The disease has distinct clinical and pathological features, and a unique molecular mechanism involving chromothripsis-mediated DNA damage.
A new study published in Cell found that TGF-beta and RAS signaling pathways are both required for lung cancer metastasis. Inhibiting RREB1, a transcription factor controlled by RAS, disabled the metastatic process in mouse models, suggesting it could be a potential new drug target.
Researchers at Memorial Sloan Kettering Cancer Center found that the spatial arrangement of three immune cells - dendritic cell, cytotoxic T cell, and helper T cell - is crucial for effective killing of cancer cells. This discovery has immediate therapeutic implications for immunotherapy treatments.
Researchers at Memorial Sloan Kettering Cancer Center have identified a new mechanism of resistance to KRAS inhibitors in pancreatic cancer, suggesting an opportunity to make the treatment more effective. The study found that a more aggressive subtype of pancreatic tumor is likely to respond well to KRAS inhibitors.
A new imaging technique developed at Memorial Sloan Kettering Cancer Center shows promise for detecting deadly forms of lung and prostate cancer. The technology targets DLL3, a ligand found on cancer cells, making them more visible on PET scans.
A new study finds that periods of fasting can reprogram the immune system's natural killer cells to better fight cancer. The research suggests that fasting may help improve immune responses and make immunotherapy more effective by training NK cells to survive in the tumor environment and produce more cytokines.
Researchers at Memorial Sloan Kettering Cancer Center developed COVET and ENVI, computational frameworks that produce detailed pictures of coordinated gene expression within spatial contexts. These tools can capture cellular heterogeneity and improve our understanding of tumor biology.
Researchers have identified mechanisms of resistance to tazemetostat in epithelioid sarcoma and rhabdoid tumors, leading to the development of a combination therapy strategy. The therapy uses an epigenetic treatment approach to target specific mutations that drive cancer growth.
A new off-the-shelf vaccine has shown encouraging early results as a potential treatment for patients with pancreatic or colorectal cancer who have certain KRAS gene mutations. The vaccine appears to stimulate the immune system to create cancer-fighting cells, delaying cancer recurrence in some patients.
Researchers at Memorial Sloan Kettering Cancer Center have engineered CAR T cells to target senescent cells, which can lead to chronic inflammation with aging. The treatment improved metabolic function in older mice and prevented decline later in life, suggesting potential benefits for diseases associated with aging.
Researchers at MSK Cancer Center have developed a way to speed up the development of nerve cells in the lab, mirroring the human brain's maturation process. By inhibiting an epigenetic barrier, scientists can accelerate the study of neurodegenerative diseases like Parkinson's and Alzheimer's.
Researchers found a code directing mRNAs to specific neighborhoods for translation, revealing the cytoplasm's compartmentalization. This discovery sheds light on fundamental cellular biology and holds promise for increasing or altering protein production in mRNA vaccines and therapies.
New research reveals that Black women are more likely to develop endometrial cancers called serous carcinoma and carcinosarcoma, which are more aggressive than those found in white women. The study also showed that Black patients have a higher risk of having copy number-high or TP53 abnormal tumors, which have worse outcomes.
Researchers at Memorial Sloan Kettering Cancer Center have found that lung cancer cells retain a 'memory' of their healthy cell counterparts, which could be exploited to improve treatment with KRAS inhibitors. Eliminating these AT1-like cells improves treatment response to the drugs.
Researchers led by Dr. Ming Li at Memorial Sloan Kettering Cancer Center investigate the molecular mechanisms of immune regulation and its role in cancer. They aim to uncover new biological insights to target the immune system for cancer therapy, building on recent advancements in immunotherapy.
Researchers have discovered that disrupting a single gene, SUV39H1, can restore the expression of multiple genes in CAR T cells, making them more potent and long-lasting. This approach has shown improved effectiveness against multiple cancers in mice, potentially expanding patient eligibility and reducing side effects.
Researchers at Memorial Sloan Kettering Cancer Center developed an open-source computational method, Spectra, to analyze single-cell transcriptomic data. The algorithm identifies functionally relevant gene expression programs and is well-suited for studying large patient cohorts.
Researchers from Memorial Sloan Kettering Cancer Center presented new findings on radiation-induced secondary cancers, a new guidance system for radiation therapy, and the consequences of insurance denials. The studies aimed to improve personalized treatment decisions for patients with rare cancer syndromes like Li-Fraumeni syndrome.
Researchers at Memorial Sloan Kettering Cancer Center discovered that prolonged activation of the STING pathway leads to desensitization and cellular signaling changes that aid cancer's spread. This finding helps explain why drugs activating STING have been unsuccessful in clinical trials.
New prediction models developed at MSK effectively identify patients at higher risk of developing lymphedema, allowing for interventions to reduce risk before surgery and closer follow-up. The models take racial differences in disease incidence into consideration, improving accuracy.
A graduate student's curiosity uncovers a previously unknown link between chromosomal instability and epigenetic alterations in cancer. The study, led by MSK researchers, reveals that chromosomal instability can drive epigenetic changes without requiring gene mutations, shedding light on the biology of advanced, drug-resistant cancers.